{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:57:25Z","timestamp":1790686645482,"version":"4.1.0"},"reference-count":45,"publisher":"Academy of Managed Care Pharmacy","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.18553\/jmcp.2026.32.10.1173","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:07:12Z","timestamp":1790683632000},"page":"1173-1188","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes"],"prefix":"10.18553","volume":"32","author":[{"given":"Meredith M.","family":"Hoog","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vallarino","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grabner","sequence":"additional","affiliation":[{"name":"Carelon Research, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Teng","sequence":"additional","affiliation":[{"name":"Carelon Research, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Terrell","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Richard","sequence":"additional","affiliation":[{"name":"Carelon Research, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","unstructured":"U.S. Centers for Disease Control and Prevention. National Diabetes Statistics Report. U.S. Centers for Disease Control and Prevention. Published 2024. Updated May 15, 2024. Accessed July 9, 2025. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0007"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16885"},{"key":"r4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0734"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S006"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0085"},{"key":"r7","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S247498"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"issue":"1","key":"r9","first-page":"S158","volume":"47","author":"ElSayed NA","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"r10","first-page":"S167","volume":"48","author":"ElSayed NA","year":"2025","journal-title":"Diabetes Care"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S008"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.08.002"},{"key":"r13","unstructured":"Mounjaro. Prescribing information. Lilly USA; 2023."},{"key":"r14","unstructured":"Ozempic. Prescribing information. Novo Nordisk, Inc; 2023."},{"key":"r15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16401"},{"key":"r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525"},{"key":"r19","unstructured":"Terrell K, Vallarino C, Maldonado Lozada J, et al. Real-World Effectiveness of Tirzepatide vs. Semaglutide on Hb A1c and Weight in GLP-1 RA Naive Patients with T2D. International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2025."},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.5586"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.5.441"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.2.153"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01470-w"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2024.89534"},{"key":"r25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14603"},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70110"},{"key":"r27","unstructured":"United States Census Bureau. American Community Survey 5-Year Data (2015-2019). U.S. Department of Commerce. Published 2019. Updated January 26, 2024. Accessed September 9, 2023. https:\/\/www.census.gov\/data\/developers\/data-sets\/acs-5year.html"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1145\/352222.352224"},{"key":"r29","unstructured":"United States Bureau of Labor Statistics. Consumer Price Index. Published 2023. Accessed July 28, 2025. https:\/\/www.bls.gov\/cpi\/home.htm"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S006"},{"issue":"1","key":"r31","first-page":"S27","volume":"48","author":"ElSayed NA","year":"2025","journal-title":"Diabetes Care"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020363010465"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.12.10"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2256"},{"issue":"2","key":"r35","first-page":"65","volume":"6","author":"Holm S","year":"1979","journal-title":"Scand J Stat Theory Appl"},{"key":"r36","doi-asserted-by":"crossref","unstructured":"Hoog M, Vallarino C, Maldonado Lozada J, et al. Real-World Effectiveness of Tirzepatide vs. Semaglutide on Hb A1c and Weight in GLP-1 RA Experienced Patients with T2D. International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2025.","DOI":"10.1016\/j.jval.2025.04.157"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16372"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2725"},{"key":"r39","unstructured":"Kosko R. Resolution of Tirzepatide Injection Product Shortage and Supply Status. US Food and Drug Administration; 2024."},{"key":"r40","unstructured":"U.S. Food & Drug Administration. FDA Drug Shortages. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. Semaglutide Injection. U.S. FDA. Published 2025. Updated February 21, 2025. Accessed July 8, 2025. https:\/\/dps.fda.gov\/drugshortages\/resolved\/semaglutide-injection"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13902"},{"key":"r42","doi-asserted-by":"publisher","DOI":"10.2337\/ds21-0108"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.08.001"},{"key":"r44","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-015-0053-5"},{"key":"r45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.04.014"}],"container-title":["Journal of Managed Care &amp; Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:08:11Z","timestamp":1790683691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.10.1173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.18553\/jmcp.2026.32.10.1173"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.10.1173","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}